ArticleFrontiers in oncology2025
Utility of extended HPV genotyping in cervical cancer screening: a prospective population-based cohort study in China.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer poses a substantial global health burden, particularly in China where it contributes substantially to incidence and mortality. Conventional HR-HPV screening tests primarily target HPV16/18, limiting efficacy in regions dominated by other oncogenic genotypes and underscoring the need for extended genotyping to refine risk-stratified approaches. Methods: This prospective cohort in Henan Province, China (2017-2020), enrolled 3,299 women aged 21-64 for baseline HR-HPV testing using an extended genotyping assay detecting 14 types and identifying HPV16/18/33/52/58. HR-HPV-positives were followed annually, negatives at year 3. Three-year cumulative CIN2+/CIN3+ risks, sensitivity, specificity, PPV, and NPV were computed independent of cytology. Results: Baseline HR-HPV positivity was 18.3%. Over 3 years, 98 CIN2+ and 60 CIN3+ cases were detected. Absolute CIN2+ risks was highest for HPV16 (32.8%), comparable for HPV18/33/58 (25-28%), with relative risks exceeding 96-fold compared to HR-HPV-negatives. Extended genotyping for HPV16/18/33/52/58 improved CIN2+/CIN3+ sensitivity to 55.1% and 60.0%, respectively (vs. 51.0% and 53.3% for HPV16/18), while maintaining specificities >93%. Conclusions: In Chinese women, non-16/18 high-risk genotypes exhibit risks comparable to HPV16/18, emphasizing the value of extended genotyping in enhancing risk-based screening sensitivity and efficiency in high-burden contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.